Myriad Genetics
its MyChoice CDx received FDA approval as the companion diagnostic for Zejula (niraparib) in ovarian cancer, and the company continues expanding its Precise MRD test into colorectal, renal and breast cancer.
- Country
- United States
- Ticker
- MYGN
Commercial
MyChoice CDx / Precise MRD
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Companion diagnostics platforms | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.